QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Entrada Therapeutics, Inc. (TRDA)

Healthcare

No action
Fundamental
2
Sentiment
1
Technical
3

Do Nothing: fundamentalScore 2 and qualitativeScore 1 are both below the required floor of 3 (live going-concern overhang, and the SHADOW branch is unavailable at flag false / qual-1), and the 20-day average dollar volume of ~$2.48M is below the $5M liquidity floor; no bullish entry regardless of the basing chart.

Analysis as of 2026-11-14· more than 2 trading days ago

Company overview

Entrada Therapeutics, Inc. is a biotechnology company focused on developing endosomal escape vehicle (EEV) therapeutics for neuromuscular diseases. Its lead product candidate, ENTR-601-44, is in preclinical development for Duchenne muscular dystrophy and myotonic dystrophy type 1. The company is headquartered in Boston, Massachusetts.

Fundamental

weak
Fundamental2
Elevated risk

Entrada faces elevated risk due to a going-concern disclosure, weak clinical data, and potential dilution.

Entrada Therapeutics is a pre-revenue DMD and ocular biotech with a debt-free balance sheet ($193.0M of cash and marketable securities against $47.3M of operating-lease liabilities) and an explicit going-concern conclusion in its Q3 2026 Form 10-Q. Collaboration revenue has effectively run out at about $4.0M trailing against roughly $136M of annual cash burn, the FY2024 profit was a one-off Vertex milestone rather than an operating result, and the October 2026 ENTR-601-45 Cohort 1 data showed only a 0.10% mean dystrophin increase, well behind approved exon-skippers whose sponsors are already filing applications. The shares trade near cash value, which limits downside, but dilution risk, binary clinical catalysts and steady insider distribution keep the fundamental picture defensive.

Sentiment

very weak
Sentiment1
Negative sentiment

Sentiment is negative, with insider selling and a severe going-concern red flag.

Dominant near-term item is the 2026-11-05 Q3 2026 report (announced confidence), received neutrally — EPS above consensus against a revenue miss and a widening loss — leaving a determinate but flat media delta (baseline polarity_score ≈ +0.01 → scoring ≈ +0.03) and unreadable retail (Reddit 403 twice). The Red-Flag Screen fires the severe going-concern / substantial-doubt flag on the explicit ASC 205-40 conclusion in the Q3 2026 10-Q filed 2026-11-05, so a severe red-flag cap applies.

Technical

fair
Technical3
Base-building

The stock is in a base-building phase, holding above short-term averages but capped by longer-term resistance.

Chart score 3 (mixed): price 5.09 holds above the SMA20 (4.83), EMA9 (5.03), EMA21 (5.02), WMA21 (4.90), DEMA14 (5.01) and the 2026-11-13 daily VWAP (5.105), with a rising low sequence off the 2026-10-14 low (4.11 -> 4.33/4.43 -> 4.51 -> 4.54 -> 4.91) and a bullish MACD cross (line -0.09 above signal -0.21, histogram +0.12 and expanding for a third session) - constructive short-term repair. Against that, the primary trend is still down: price is 9.1% below the SMA50 (5.60) and 39.8% below the SMA200 (8.46), ADX has decayed from ~30 on 2026-11-02 to 21.0 (the old downtrend losing force rather than an uptrend asserting itself), and RSI 49.9 / Williams %R -32.5 are neutral. Liquidity is thin: the 20-session mean of close x volume is roughly $2.48M, about half the $5M floor. Independently of the chart, fundamentalScore 2 and qualitativeScore 1 (both below the required floor of 3, with a live ASC 205-40 going-concern disclosure upstream) hard-block any long entry, and the SHADOW branch is unavailable (shadow flag false, qualitativeScore = 1), so no trade plan is constructed.

You’re looking at 2026-11-14 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.